MedTrace Logo

Efficacy of Curcumin in Oral Submucous Fibrosis

NCT03511261 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2018-04-27

No results posted yet for this study

Summary

The purpose of the study is to determine whether the formulations of curcumin will effect the clinical signs and symptoms and histopathological features in patients with clinical stage 2 oral submucous fibrosis (OSMF).

Conditions

  • Oral Submucous Fibrosis

Interventions

DRUG

10% Curcumin mucoadhesive gel

Group 1 10%of mucoadhesive gel for topical application two times per day.

DRUG

Curcumin capsules 500mg

Group 2 curcumin 500 mg capsules for oral intake two times per day

DRUG

5% curcumin mucoadhesive gel + Curcumin capsules 250 mg

Group 3 5% curcumin mucoadhesive gel topical application two times per day + curcumin 250 mg capsules for oral intake two times per day

DRUG

Placebo capsule

Group 4 placebo capsules for oral intake two times per day

Sponsors & Collaborators

  • H.K.E.S's S.Nijalingappa Institute of Dental Science and Research

    lead OTHER

Principal Investigators

  • Syeda Arshiya Ara, MDS · HKE'S S.N Institute of dental sciences & research center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
14 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03511261 on ClinicalTrials.gov